Mangoceuticals advances research on patented respiratory illness technology

Mangoceuticals (MGRX) announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses, specifically within the poultry industry. The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization based in Mysuru, India, to conduct independent efficacy studies aimed at developing an antiviral solution for respiratory illnesses in humans. These studies are based on the Company’s acquisition of patented respiratory illness prevention technology from IntraMont Technologies. Phase I animal studies have already demonstrated significant efficacy in reducing lung viral load, and the compounds are now advancing into Phase II animal studies.